Molecular Beacon reverse transcription-PCR of human chorionic gonadotropin-β-3, -5, and -8 mRNAs has prognostic value breast cancer

Clinical Chemistry

Volumn 49, Issue 7, 2003, Pages 1074-1080

  Span, Paul N ^a   Manders, Peggy ^a   Heuvel, Joop J T M ^a   Thomas, Chris M G ^a   Bosch, Remko R ^a   Beex, Louk V A M ^a   Sweep, C G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; MESSENGER RNA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HAZARD ASSESSMENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

ACTINS; ADULT; BREAST NEOPLASMS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; FEMALE; HUMANS; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0037596871     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.7.1074     Document Type: Article

References (34)

1. Bates SE, Longo DL. Tumor markers: value and limitations in the management of cancer patients. Cancer Treat Rev 1985;12:163-207.
2. Mann K, Saller B, Hoermann R. Clinical use of hCG and hCG β determinations. Scand J Clin Lab Invest Suppl 1993;216:97-104.
3. Marcillac I, Troalen F, Bidart JM, Ghillani P, Ribrag V, Escudier B, et al. Free human chorionic gonadotropin β subunit in gonadal and nongonadal neoplasms. Cancer Res 1992;52:3901-7.
4. Iles RK, Persad R, Trivedi M, Sharma KB, Dickinson A, Smith P, et al. Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker in bladder cancer. Br J Urol 1996;77:61-9.
5. Sheaff MT, Martin JE, Badenoch DF, Baithun SI. βhCG as a prognostic marker in adenocarcinoma of the prostate. J Clin Pathol 1996;49:329-32.
6. Span PN, Thomas CM, Heuvel JJ, Bosch RR, Schalken JA, vd Locht L, et al. Analysis of expression of chorionic gonadotropin transcripts in prostate cancer by quantitative TaqMan and a modified Molecular Beacon RT-PCR. J Endocrinol 2002;172:489-95.
7. Agnantis NJ, Patra F, Khaldi L, Filis S. Immunohistochemical expression of subunit β hCG in breast cancer. Eur J Gynaecol Oncol 1992;13:461-6.
8. Bellet D, Lazar V, Bieche I, Paradis V, Giovangrandi Y, Paterlini P, et al. Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin β genes normally transcribed in trophoblastic cells. Cancer Res 1997;57:516-23.
9. Bieche I, Lazar V, Nogues C, Poynard T, Giovangrandi Y, Bellet D, et al. Prognostic value of chorionic gonadotropin β gene transcripts in human breast carcinoma. Clin Cancer Res 1998;4:671-6.
10. Giovangrandi Y, Parfait B, Asheuer M, Olivi M, Lidereau R, Vidaud M, et al. Analysis of the human CGB/LHB gene cluster in breast tumors by real-time quantitative RT-PCR assays. Cancer Lett 2001;168:93-100.
11. Policastro PF, Daniels-McQueen S, Carle G, Boime I. A map of the hCG β-LH β gene cluster. J Biol Chem 1986;261:5907-16.
12. Lazar V, Diez SG, Laurent A, Giovangrandi Y, Radvanyi F, Chopin D, et al. Expression of human chorionic gonadotropin β subunit genes in superficial and invasive bladder carcinomas. Cancer Res 1995;55:3735-8.
13. Tyagi S, Kramer FR. Molecular beacons: probes that fluoresce upon hybridization. Nat Biotechnol 1996;14:303-8.
14. EORTC Breast Cancer Cooperative Group. Revision of standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 1980;16:1513-6.
15. Tsourkas A, Behlke MA, Bao G. Structure-function relationships of shared-stem and conventional molecular beacons. Nucleic Acids Res 2002;30:4208-15.
16. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B 1972;34:187-220.
18. Acevedo HF, Tong JY, Hartsock RJ. Human chorionic gonadotropin-β subunit gene expression in cultured human fetal and cancer cells of different types and origins. Cancer 1995;76:1467-75.
19. Tanaka Y, Kuwabara K, Okazaki T, Fujita T, Oizumi I, Kaiho S, et al. Gonadotropins stimulate growth of MCF-7 human breast cancer cells by promoting intracellular conversion of adrenal androgens to estrogens. Oncology 2000;59:19-23.
20. Wang J, Luo F, Lu JJ, Chen PK, Liu P, Zheng W. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer 2002;97:163-7.
21. Reimer T, Koczan D, Muller H, Friese K, Krause A, Thiesen HJ, et al. Human chorionic gonadotrophin-β transcripts correlate with progesterone receptor values in breast carcinomas. J Mol Endocrinol 2000;24:33-41.
22. Wasylyk B, Hahn SL, Giovane A. The Ets family of transcription factors. Eur J Biochem 1993;211:7-18.
23. Liu AY, Corey E, Vessella RL, Lange PH, True LD, Huang GM, et al. Identification of differentially expressed prostate genes: increased expression of transcription factor ETS-2 in prostate cancer. Prostate 1997;30:145-53.
24. Goshen R, Gonik B, Ariel I, Weiss Y, de-Groot N, Hochberg A. High levels of maternal serum human chorionic gonadotropin in Down syndrome pregnancies: the possible role of a transcription factor on chromosome 21. Fetal Diagn Ther 1999;14:106-11.
25. Johnson W, Jameson JL. Role of Ets2 in cyclic AMP regulation of the human chorionic gonadotropin β promoter. Mol Cell Endocrinol 2000;165:17-24.
26. Watabe T, Yoshida K, Shindoh M, Kaya M, Fujikawa K, Sato H, et al. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer 1998;77:128-37.
27. Pacheco MM, Nishimoto IN, Mourao Neto M, Mantovani EB, Brentani MM. Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis. Int J Biol Markers 2001;16:62-8.
28. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-28.
29. Soares J, Pinto AE, Cunha CV, Andre S, Barao I, Sousa JM, et al. Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumor progression. Cancer 1999;85:112-8.
30. Campain JA, Gutkin DW, Cox GS. Differential DNA methylation of the chorionic gonadotropin β-subunit multigene family. Mol Endocrinol 1993;7:1331-46.
31. Rennie PS, Nelson CC. Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Rev 1998-1999;17:401-9.
32. Santourlidis S, Florl A, Ackermann R, Wirtz HC, Schulz WA. High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 1999;39:166-74.
33. Ayyadevara S, Thaden JJ, Shmookler Reis RJ. Discrimination of primer 3′-nucleotide mismatch by Taq DNA polymerase during polymerase chain reaction. Anal Biochem 2000;284:11-8.
34. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983;52:1551-7.